// App-Quantinova.ai

437 : Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Researchers

Presenter

  • Nina Shah

Principal Investigators

  • Michel Delforge

  • Jess F. San-Miguel

  • Kaitlyn B. Bertin

  • Muna J Tahir

  • Hannah B. Lewis

  • Julie Wang

  • Julia Braverman

  • Timothy B. Campbell

  • Devender Dhanda

  • Nikhil C. Munshi

Medical Centers

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Clinica Universidad de Navarra, Pamplona, Spain

  • ICON plc, San Francisco, CA

  • NCRI, London, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute,, Boston, MA

Locations

  • United States

  • Belgium

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • II

Study Id's

  • NCT03361748

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved